← Back to Search

Overdose Notification for Opioid Use Disorder (AESOPS-2 Trial)

N/A
Waitlist Available
Led By Jason Doctor, PhD
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The clinician prescribed a qualifying scheduled drug to a patient in the 12 months prior to their non-fatal or fatal overdose
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 13 months (6 months pre-intervention, 30-day washout period, 6 months post-intervention)
Awards & highlights

AESOPS-2 Trial Summary

This trial is testing if making doctors more aware of the dangers of opioid prescribing will reduce the amount of opioids prescribed.

Who is the study for?
The AESOPS-2 trial is for healthcare providers who have prescribed opioids or similar drugs to adult patients before those patients experienced a non-fatal or fatal overdose. Providers must be part of a participating health system, and the patient's overdose should have occurred within a year of observation.Check my eligibility
What is being tested?
This study tests whether sending notifications about negative outcomes (like overdoses) to doctors can reduce unnecessary opioid prescriptions. It aims to make the consequences of overprescribing more noticeable to healthcare professionals.See study design
What are the potential side effects?
Since this trial involves an intervention targeting prescribers rather than direct medical treatment, there are no traditional side effects. However, it may impact prescribing habits and potentially affect patient care indirectly.

AESOPS-2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was prescribed a specific medication before my overdose.

AESOPS-2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~13 months (6 months pre-intervention, 30-day washout period, 6 months post-intervention)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 13 months (6 months pre-intervention, 30-day washout period, 6 months post-intervention) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Weekly MME
Secondary outcome measures
Change in the Proportion of Patients Prescribed at least 50 Daily MME

AESOPS-2 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Overdose Notification GroupExperimental Treatment1 Intervention
The overdose notifications will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses.
Group II: Control GroupActive Control1 Intervention
Physicians in the control group will receive no notification of their patient's fatal or nonfatal overdose.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Overdose Notification
2023
N/A
~70

Find a Location

Who is running the clinical trial?

University of Southern CaliforniaLead Sponsor
905 Previous Clinical Trials
1,596,217 Total Patients Enrolled
AltaMed Health Services CorporationOTHER
8 Previous Clinical Trials
31,440 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,669 Previous Clinical Trials
28,005,053 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this survey currently accessible to participants?

"According to the clinicaltrials.gov portal, this particular medical trial is not presently recruiting patients. Initially posted on November 1st 2022 and most recently updated on October 10th 2022, it has stopped taking applications; however, there are 291 other trials open for enrollment at this time."

Answered by AI
Recent research and studies
Contemporary Clinical TrialsJournal
The Protocol of the Application of Economics & Social Psychology to Improve Opioid Prescribing Safety Trial 2 (AESOPS-2): Availability of Opioid Harm
Kelley, Marcella A., Stephen D. Persell, Jeffrey A. Linder, Mark W. Friedberg, Daniella Meeker, Craig R. Fox, Noah J. Goldstein, et al.. 2022. “The Protocol of the Application of Economics & Social Psychology to Improve Opioid Prescribing Safety Trial 2 (AESOPS-2): Availability of Opioid Harm”. Contemporary Clinical Trials. Elsevier BV. doi:10.1016/j.cct.2021.106650.
Contemporary Clinical TrialsJournal
The Protocol of the Application of Economics & Social Psychology to Improve Opioid Prescribing Safety Trial 2 (AESOPS-2): Availability of Opioid Harm
Kelley, Marcella A., Stephen D. Persell, Jeffrey A. Linder, Mark W. Friedberg, Daniella Meeker, Craig R. Fox, Noah J. Goldstein, et al.. 2022. “The Protocol of the Application of Economics & Social Psychology to Improve Opioid Prescribing Safety Trial 2 (AESOPS-2): Availability of Opioid Harm”. Contemporary Clinical Trials. Elsevier BV. doi:10.1016/j.cct.2021.106650.
clinicaltrials.govStudy
AESOPS Trial 2 (AESOPS-2): Availability of Opioid Harm
Jason Doctor 2023. "AESOPS Trial 2 (AESOPS-2): Availability of Opioid Harm". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04758637.
~28 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top